GlaxoSmithKline's diabetes contender albiglutide nabs EU approval

European officials gave a green light to GlaxoSmithKline's once-weekly diabetes drug Eperzan (albiglutide). The GLP-1 drug is awaiting FDA approval, with a decision expected next month. It's a key win for Glaxo ($GSK), which needs new products to pump up sales as its top-seller, Advair, grows increasingly vulnerable to generic competition. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.